Summary
For Year 2026-27, Kabra Drugs reports the following shareholding: Total Promoters at 0%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 100%. This breakdown provides a quick snapshot of ownership distribution for Kabra Drugs in 2026-27.
Kabra Drugs FAQs
As of 04-2026, the promoter shareholding in Kabra Drugs stands at 0% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Kabra Drugs is 0% and 0% respectively.
The retail shareholding of the Kabra Drugs is 100%.
Changes in shareholding patterns of Kabra Drugs can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Kabra Drugs are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
